For the first time, our data suggest a limited or missing influence of DAAs therapy on thyroid function and autoimmunity of patients studied, as deduced by the unchanged number of HT patients in IFN-α group and the absence of new cases observed in both groups. This evidence concerns the gene IFNA17 and hematocrit.